MS Drug Candidate May Also Treat Ulcerative Colitis

MS Drug Candidate May Also Treat Ulcerative Colitis
receptos UC drugReceptos, Inc., a San Diego-based biotechnology company, announced promising new clinical data for its drug candidate RPC1063 for ulcerative colitis. The drug was first discovered and synthesized at The Scripps Research Institute (TSRI) by the research groups of Professor Hugh Rosen and Professor Ed Roberts. Ulcerative colitis (UC) is a key form of inflammatory bowel disease (IBD), characterized by chronic inflammation in the colon and rectum. This pathological condition together with Crohn's disease affects more than one million people nationally, according to the U.S. Centers for Disease Control and Prevention. Moreover, the disease causes major morbidity globally, and its incidence and prevalence seems to be increasing with time. The pathogenesis of UC seems to be due to an uncontrolled immune response to an unknown environmental stimulus in the large bowel. Although there is treatment for some patients with ulcerative colitis, according to the Crohn's and Colitis Foundation of America, the disease progresses in 23 to 45% of patients in spite of medication, and in the end surgical removal of all or part of the colon is required. This clinical trial, sponsored by Receptos, Inc., is called TOUCHSTONE, and i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *